Madrigal Pharmaceuticals/ US5588681057 /
2024-05-03 9:59:55 PM | Chg. +13.56 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
229.65USD | +6.28% | 33,366 Turnover: 7.66 mill. |
-Bid Size: - | -Ask Size: - | 234.47 | 222.43 |
GlobeNewswire
04-23
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, ...
GlobeNewswire
04-16
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
04-09
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of...
GlobeNewswire
04-05
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for ...
GlobeNewswire
04-03
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
03-19
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
GlobeNewswire
03-14
FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
GlobeNewswire
03-14
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Pati...
GlobeNewswire
03-06
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
03-05
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Res...
GlobeNewswire
02-28
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Fi...
GlobeNewswire
02-21
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
02-08
Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in th...
GlobeNewswire
02-06
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
01-22
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
01-04
Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG ...
GlobeNewswire
01-03
Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
2023-12-22
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2023-11-27
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2023-11-21
Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer